Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Tevogen Bio Holdings (Nasdaq: TVGN) announces CEO Dr. Ryan Saadi's participation in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025, at The Liberty Science Center in Jersey City. Dr. Saadi will join a panel discussion titled 'Paths to Liquidity: Strategies for Adapting to a Volatile Market,' alongside executives from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference aims to connect investors, BD professionals, academic collaborators, and biopharmaceutical industry executives to promote strategic partnerships, funding opportunities, and healthcare innovation. The event features 1:1 partnering sessions, company pitch presentations, Industry Connections Desk, exhibits, and networking opportunities.
Tevogen Bio Holdings (Nasdaq: TVGN) annuncia la partecipazione del CEO Dr. Ryan Saadi alla Quindicesima Conferenza Annuale di Bio Partnering di BioNJ che si terrà il 13 maggio 2025, presso il Liberty Science Center di Jersey City. Il Dr. Saadi parteciperà a un panel intitolato 'Percorsi verso la Liquidità: Strategie per Adattarsi a un Mercato Volatile', insieme a dirigenti di J.P. Morgan, RSM e Cantor Fitzgerald.
La conferenza ha l'obiettivo di connettere investitori, professionisti del business development, collaboratori accademici e dirigenti dell'industria biopharmaceutica per promuovere partnership strategiche, opportunità di finanziamento e innovazione nel settore sanitario. L'evento prevede sessioni di partnering 1:1, presentazioni aziendali, un desk per le connessioni industriali, mostre e opportunità di networking.
Tevogen Bio Holdings (Nasdaq: TVGN) anuncia la participación del CEO Dr. Ryan Saadi en la Quinceava Conferencia Anual de Bio Partnering de BioNJ que se llevará a cabo el 13 de mayo de 2025, en el Liberty Science Center de Jersey City. El Dr. Saadi se unirá a un panel titulado 'Caminos hacia la Liquidez: Estrategias para Adaptarse a un Mercado Volátil', junto a ejecutivos de J.P. Morgan, RSM y Cantor Fitzgerald.
La conferencia tiene como objetivo conectar a inversores, profesionales de desarrollo de negocios, colaboradores académicos y ejecutivos de la industria biofarmacéutica para promover asociaciones estratégicas, oportunidades de financiamiento e innovación en salud. El evento contará con sesiones de emparejamiento 1:1, presentaciones de empresas, un escritorio de conexiones industriales, exhibiciones y oportunidades de networking.
Tevogen Bio Holdings (Nasdaq: TVGN)는 2025년 5월 13일 저지 시티의 리버티 사이언스 센터에서 열리는 BioNJ 제15회 연례 바이오 파트너링 컨퍼런스에 CEO Dr. Ryan Saadi가 참석한다고 발표했습니다. Dr. Saadi는 J.P. Morgan, RSM 및 Cantor Fitzgerald의 경영진과 함께 '유동성 경로: 변동성 시장에 적응하기 위한 전략'이라는 제목의 패널 토론에 참여할 예정입니다.
이 컨퍼런스는 투자자, 비즈니스 개발 전문가, 학술 협력자 및 생명공학 산업 경영진을 연결하여 전략적 파트너십, 자금 조달 기회 및 의료 혁신을 촉진하는 것을 목표로 합니다. 이 행사는 1:1 파트너링 세션, 회사 발표, 산업 연결 데스크, 전시회 및 네트워킹 기회를 포함합니다.
Tevogen Bio Holdings (Nasdaq: TVGN) annonce la participation de son PDG Dr. Ryan Saadi à la Quinzième Conférence Annuelle de Bio Partenariat de BioNJ qui se tiendra le 13 mai 2025 au Liberty Science Center de Jersey City. Le Dr. Saadi participera à une table ronde intitulée 'Chemins vers la Liquidité : Stratégies pour s'adapter à un Marché Volatile', aux côtés de dirigeants de J.P. Morgan, RSM et Cantor Fitzgerald.
La conférence vise à connecter des investisseurs, des professionnels du développement commercial, des collaborateurs académiques et des dirigeants de l'industrie biopharmaceutique pour promouvoir des partenariats stratégiques, des opportunités de financement et des innovations en matière de santé. L'événement propose des sessions de partenariat 1:1, des présentations d'entreprises, un bureau de connexions industrielles, des expositions et des opportunités de réseautage.
Tevogen Bio Holdings (Nasdaq: TVGN) gibt die Teilnahme von CEO Dr. Ryan Saadi an der 15. jährlichen Bio Partnering Konferenz von BioNJ bekannt, die am 13. Mai 2025 im Liberty Science Center in Jersey City stattfindet. Dr. Saadi wird an einer Podiumsdiskussion mit dem Titel 'Weg zur Liquidität: Strategien zur Anpassung an einen volatilen Markt' teilnehmen, zusammen mit Führungskräften von J.P. Morgan, RSM und Cantor Fitzgerald.
Die Konferenz zielt darauf ab, Investoren, BD-Profis, akademische Partner und Führungskräfte der biopharmazeutischen Industrie zu vernetzen, um strategische Partnerschaften, Finanzierungsmöglichkeiten und Innovationen im Gesundheitswesen zu fördern. Die Veranstaltung umfasst 1:1-Partnering-Sitzungen, Unternehmenspräsentationen, einen Industry Connections Desk, Ausstellungen und Networking-Möglichkeiten.
- None.
- None.
WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.
The conference, held on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, historically brings together investors, BD professionals, academic collaborators, innovators and biopharmaceutical industry executives to foster strategic partnerships, drive funding, and accelerate collaboration, with the ultimate goal of advancing medical innovation and transforming the future of healthcare.
“I look forward to joining in the upcoming panel discussion hosted by BioNJ,” said Dr. Saadi. “This is a critical moment for the biotechnology industry to address market volatility and its potential impact on patient outcomes. The topic is closely aligned with Tevogen Bio’s mission to advance accessibility and affordability to lifesaving treatments.”
“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to welcome Dr. Saadi and his fellow panelists to share their invaluable insights during “Paths to Liquidity: Strategies for Adapting to a Volatile Market”. Attendees are certain to walk away with meaningful, actionable takeaways.”
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When and where is Tevogen Bio (TVGNW) participating in the BioNJ Conference?
Who are the panelists joining Tevogen Bio's CEO in the market volatility discussion?
What is the focus of Tevogen Bio's panel discussion at the BioNJ Conference?
What activities are featured at the 2025 BioNJ Conference?
